Integral Health Asset Management
ATRA icon

Integral Health Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Integral Health Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,350
Closed -$1.63M – 67
2022
Q2 		$1.63M Sell
8,350
-3,650
-30% -$596K 0.33% 60
2022
Q1 		$2.79M Buy
12,000
+4,000
+50% +$1.27M 0.73% 50
2021
Q4 		$3.15M Hold
8,000
– – 0.87% 38
2021
Q3 		$3.58M Buy
+8,000
New +$2.87M 1.03% 40

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Maverick Capital
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Integral Health Asset Management's ATRA Position: Q3 2022 in Review

Integral Health Asset Management sold out of Atara Biotherapeutics (ATRA) in Q3 2022, closing a stake of 8,350 shares — an estimated $1.63M sold.

Integral Health Asset Management first reported a position in ATRA in Q3 2021 and held it in 4 quarters. The position peaked at $3.58M in Q3 2021. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

  • Integral Health Asset Management reported no remaining Atara Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Integral Health Asset Management sold 8,350 Atara Biotherapeutics shares in Q3 2022, an estimated $1.63M.
  • Integral Health Asset Management first reported a position in Atara Biotherapeutics in Q3 2021 and held it in 4 quarters.
  • Integral Health Asset Management's Atara Biotherapeutics position peaked at $3.58M in Q3 2021.
  • 154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on Integral Health Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.